NEW YORK, Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST).Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=159228&from=4CLASS PERIOD: November 7, 2024 to July 8, ...

Core Insights - RxSight, Inc. has appointed Raymond W. Cohen to its Board of Directors, which is expected to enhance the company's growth strategy and market reach in the ophthalmic medical device sector [1][2]. Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on providing customized vision solutions for patients post-cataract surgery [4]. - The company's flagship product, the RxSight® Light Adjustable Lens system, is the first commercially available intraocular lens technology that can be adjusted after surgery, allowing for tailored vision outcomes [4]. Leadership Experience - Raymond W. Cohen brings over 40 years of experience in the medical technology industry, having co-founded Axonics, Inc., which achieved over $1 billion in revenue within four years of its launch and was acquired by Boston Scientific for $3.7 billion in 2024 [2][3]. - Cohen has held various leadership roles in multiple healthcare companies, indicating a strong background in scaling medical technology businesses [3]. Strategic Vision - Cohen sees significant potential for RxSight to strengthen its position in the premium intraocular lens market and aims to support the company's growth in revenue and profits [3]. - The company aims to expand the reach of its Light Adjustable Lens system, thereby benefiting more physicians and patients [2][3].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities, with the case pending in the U.S. District Court for the Central District of California [2]. - The company allegedly failed to disclose "adoption challenges" for its products, despite promoting strong sales figures, leading to a slowdown in LAL utilization first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, resulting in a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The Class Period for the RxSight securities is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. Group 2: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its business performance, including issues with product adoption and overstated demand [4]. - It is claimed that RxSight was unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. - The misleading statements led to investor damages when the true situation was revealed [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the financial results led to a nearly 38% drop in the price of RxSight stock [5].

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submiss ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] Group 1: Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The LAL can be customized post-surgery through non-invasive light treatments, utilizing a Light Delivery Device (LDD) to optimize vision based on individual patient needs [3] Group 2: Allegations and Market Impact - The lawsuit claims that RxSight failed to disclose "adoption challenges" in its products while promoting strong sales of LAL and LDD, despite experiencing a slowdown in LAL utilization first noted in 2024 [4] - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a "softening" market that began in the second half of 2024, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38%, from $12.79 to $7.95 per share [6]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Group 1 - A securities class action lawsuit has been filed against RxSight, Inc. on behalf of investors who purchased its securities [1] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and it alleges securities fraud and unlawful business practices [6] - RxSight reported significant declines in sales of its Light Delivery Device and lower usage of light adjustable intraocular lenses, leading to an overall revenue shortfall [6] Group 2 - The company cut its full year 2025 guidance by approximately $42.5 million due to "adoption challenges" affecting sales [6] - Following the negative news, RxSight's stock price dropped by $4.84, a decrease of 37.84%, closing at $7.95 per share on July 9, 2025 [6] - The lead plaintiff deadline for the lawsuit is September 22, 2025, encouraging affected investors to contact the law firm for more information [6]

CLASS PERIOD: November 7, 2024 to July 8, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025 ...